# Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients

> **NCT00391638** · PHASE2,PHASE3 · COMPLETED · sponsor: **French National Agency for Research on AIDS and Viral Hepatitis** · enrollment: 56 (actual)

## Conditions studied

- Hepatitis B
- HIV Infections

## Interventions

- **DRUG:** TRUVADA (EMTRICITABINE + TENOFOVIR DF)
- **BIOLOGICAL:** PEGASYS 180μg (Interféron pégylé alpha -2a)

## Key facts

- **NCT ID:** NCT00391638
- **Lead sponsor:** French National Agency for Research on AIDS and Viral Hepatitis
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2011-05
- **Final completion:** 2012-10
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2015-01-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00391638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00391638, "Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00391638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*